How Adaptogens Work: Cortisol, Neurotransmitters, and the Multi-System Stress Response

London, United Kingdom — 31 March 2026

Adaptogens are often described as "stress modulators," but this shorthand obscures the genuinely complex pharmacology underlying their effects. These botanicals do not operate through a single receptor or pathway. Instead, they interact with multiple physiological systems simultaneously — the HPA axis, neurotransmitter networks, and inflammatory signalling cascades — which is both the source of their therapeutic versatility and the reason they are so difficult to study in conventional clinical frameworks.

Cortisol Dynamics: Beyond Simple Suppression

The hypothalamic-pituitary-adrenal axis governs the body's cortisol response. Under acute stress, cortisol rises appropriately — mobilising energy, sharpening focus, and suppressing non-essential functions. The problem arises with chronic stress, where cortisol remains persistently elevated or, in burnout states, becomes blunted and dysregulated. The diurnal cortisol curve — high in the morning, tapering through the day — flattens.

Adaptogens do not simply suppress cortisol the way pharmaceutical interventions might. The clinical data suggests they restore cortisol dynamics toward a healthier pattern. Ashwagandha's withanolides attenuate corticotropin-releasing hormone (CRH) at the hypothalamic level, effectively turning down the volume on the stress signal before it cascades through the full HPA axis. Rhodiola's salidroside appears to modulate ACTH sensitivity at the pituitary, adjusting the gain of the system rather than blocking it. The result in both cases is not cortisol suppression but cortisol normalisation — a distinction with significant clinical and commercial implications.

For formulators, this bidirectional modulation is the key selling point: the same extract may help an overstressed executive with elevated evening cortisol and an exhausted shift worker with a flattened morning cortisol response. This is pharmacologically unusual and commercially valuable.

Neurotransmitter Modulation: Multiple Targets, Softer Effects

Each major adaptogen interacts with neurotransmitter systems in distinct ways, which explains why different adaptogens are suited to different functional outcomes.

Ashwagandha and GABA: Withanolides are positive allosteric modulators of GABA-A receptors — the same receptor family targeted by benzodiazepines, though with far less potency and no addictive potential. This GABAergic activity underpins ashwagandha's anxiolytic and sleep-promoting effects. Clinical trials using 300 mg of KSM-66 twice daily have shown improvements in sleep onset latency and sleep quality scores comparable to low-dose pharmaceutical sleep aids in mild insomnia populations. For B2B buyers, this positions ashwagandha as a versatile ingredient bridging the stress and sleep categories — two of the fastest-growing supplement segments globally.

Rhodiola and monoamines: Salidroside influences serotonin and dopamine metabolism, partly through mild inhibition of monoamine oxidase (MAO) and partly through modulation of serotonin transporter activity. This mechanism aligns with rhodiola's clinical profile: improvements in mental fatigue, sustained attention, and resilience under cognitive stress. European studies on healthcare workers during demanding shift schedules have demonstrated statistically significant improvements in cognitive accuracy and reduced burnout scores after 4–8 weeks of SHR-5 rhodiola supplementation. The effects are subtle — participants do not report feeling "stimulated" but rather "less depleted."

Lion's mane and nerve growth factor: Hericium erinaceus occupies a unique position in the adaptogen-adjacent space. Its hericenones and erinacines stimulate nerve growth factor (NGF) synthesis — a mechanism entirely distinct from classical HPA axis modulation. NGF promotes neuronal growth, maintenance, and myelination, with implications for cognitive function, memory consolidation, and potentially neurodegenerative disease. A 2020 double-blind trial in older adults with mild cognitive impairment showed significant improvements in cognitive function scores after 16 weeks of lion's mane supplementation. For B2B buyers, lion's mane represents a differentiated cognitive-health ingredient that complements rather than competes with classical stress-adaptogens.

Inflammatory Signalling: The Overlooked Pathway

Chronic psychological stress drives systemic low-grade inflammation through sustained cortisol-mediated immune dysregulation. Elevated pro-inflammatory cytokines — particularly IL-6, TNF-α, and IL-1β — are consistently observed in chronically stressed populations and are increasingly linked to fatigue, mood disturbance, and cognitive impairment. This "inflammatory theory of stress" has reframed how researchers understand adaptogen mechanisms.

Multiple adaptogens inhibit NF-κB, the master transcription factor controlling inflammatory gene expression. Ashwagandha's withaferin A is a potent NF-κB inhibitor in preclinical models. Reishi's triterpenoids (ganoderic acids) suppress TNF-α and IL-6 production in both in vitro and animal studies. Holy basil's ursolic acid demonstrates similar anti-inflammatory activity. This converging anti-inflammatory action may explain why adaptogens produce broad, non-specific improvements in wellbeing rather than targeting a single symptom.

Reishi's dual role is particularly noteworthy for formulators. Its beta-glucans simultaneously support immune surveillance (upregulating natural killer cell activity) while its triterpenoids dampen excessive inflammatory signalling. This immune-modulating duality — promoting appropriate immune responses while suppressing inappropriate inflammation — makes reishi a compelling ingredient for formulations targeting calm, immune resilience, and recovery.

The Multi-System Nature: Why It Matters Commercially

The multi-target pharmacology of adaptogens is both their greatest strength and their greatest formulation challenge. A single adaptogen like ashwagandha simultaneously modulates cortisol, GABA, and NF-κB — meaning it can legitimately support stress, sleep, and inflammation claims. For product development teams, this enables efficient formulations where one well-dosed hero ingredient addresses multiple consumer need states. However, it also complicates clinical substantiation, because regulators prefer single-mechanism, single-claim frameworks that adaptogens inherently resist.

What This Means for the United Kingdom

UK brands developing adaptogen formulations should align ingredient selection with specific, defensible functional claims rather than broad "stress support" positioning. Ashwagandha is best substantiated for stress and sleep; rhodiola for mental fatigue and cognitive resilience; reishi for immune modulation and calm; lion's mane for cognitive function. The MHRA and ASA increasingly expect claim specificity backed by extract-specific (not generic botanical) evidence. For B2B suppliers, providing customers with mechanism-of-action summaries tied to specific standardised extracts — rather than generic adaptogen marketing — is becoming a competitive differentiator in the UK market.

Many of the products discussed are manufactured in partnership with UK formulators including Supplement Factory.